Physician profile
Ahmed Ali
NPI 1275896318
$18,909.70
in general payments reported to CMS, 2019-2025
63 companies · $7,928 in 2025
The $7,928 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,806 · 2020: $726 · 2021: $1,176 · 2022: $914 · 2023: $1,973 · 2024: $4,386 · 2025: $7,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,031 · Consulting Fee: $3,825 · Travel and Lodging: $592 · Education: $540 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,030.58 |
| Consulting Fee | $3,825.00 |
| Travel and Lodging | $592.41 |
| Education | $540.25 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,397.24 | 2021-2025 | Zynyz, Jakafi, Monjuvi |
| Janssen Biotech, INC. | $2,055.70 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals LP | $1,756.12 | 2019-2025 | Calquence, Imfinzi, Tagrisso |
| Novartis Pharmaceuticals Corporation | $1,075.86 | 2019-2025 | |
| Daiichi Sankyo INC. | $898.33 | 2019-2025 | Enhertu, Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $825.51 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $716.44 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Regeneron Healthcare Solutions, INC. | $627.12 | 2023-2025 | Libtayo, Lynozyfic |
| Abbvie INC. | $603.89 | 2019-2025 | |
| Celgene Corporation | $488.95 | 2019-2025 | Reblozyl, Opdivo |
| Seagen INC. | $427.21 | 2020-2023 | Tukysa |
| Pfizer INC. | $426.73 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $411.50 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $338.61 | 2022-2025 | Opdivo, Augtyro, Krazati |
| Genzyme Corporation | $251.84 | 2019-2024 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $222.23 | 2021-2025 | Trodelvy |
| Amgen INC. | $221.20 | 2019-2024 | Tepezza |
| Lilly USA, LLC | $208.96 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genmab U.S., INC. | $181.00 | 2023-2025 | Epkinly |
| Clovis Oncology, INC. | $157.72 | 2019-2020 | |
| Glaxosmithkline, LLC. | $153.28 | 2019-2025 | Jemperli, Benlysta, Zejula |
| Astellas Pharma US INC | $146.66 | 2019-2025 | Padcev, Vyloy |
| Jazz Pharmaceuticals INC. | $133.97 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.77 | 2019-2025 | |
| Stemline Therapeutics INC. | $123.84 | 2023-2025 | Orserdu |
| Blueprint Medicines Corporation | $122.32 | 2023-2024 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $121.45 | 2019-2023 | |
| Dendreon Pharmaceuticals LLC | $118.09 | 2024-2025 | Provenge |
| Exelixis INC. | $117.70 | 2021-2025 | Cabometyx |
| Kyowa Kirin, INC. | $116.03 | 2021-2023 | Poteligeo |
| Syndax Pharmaceuticals, INC. | $97.88 | 2025 | |
| Pharmacosmos Therapeutics INC. | $91.31 | 2025 | Monoferric |
| Genentech USA, INC. | $88.21 | 2019-2025 | Tecentriq |
| Tempus Ai, INC | $82.62 | 2024 | Xt Cdx |
| Progenics Pharmaceuticals, INC. | $81.17 | 2022 | |
| Alexion Pharmaceuticals, INC. | $81.15 | 2025 | Ultomiris |
| Emd Serono, INC. | $66.67 | 2019-2024 | |
| G1 Therapeutics, INC. | $49.64 | 2022 | |
| Kite Pharma, INC. | $49.50 | 2023 | Yescarta |
| Chiesi USA, INC. | $45.46 | 2023 | Ferriprox |
| Sanofi-Aventis U.S. LLC | $45.07 | 2024 | |
| Boston Scientific Corporation | $44.36 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Coherus Oncology, INC. | $43.70 | 2025 | Loqtorzi |
| Tersera Therapeutics LLC | $39.24 | 2023 | Zoladex |
| Beone Medicines USA, INC. | $32.59 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $31.96 | 2023 | Krazati |
| Tactile Systems Technology INC | $31.15 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Janssen Pharmaceuticals, INC | $30.54 | 2019-2024 | Rybrevant |
| Beigene USA, INC. | $27.37 | 2023 | Brukinsa |
| Helsinn Therapeutics (U.S.), INC. | $25.87 | 2024 | Akynzeo |
| Morphosys, US INC. | $24.93 | 2023 | Monjuvi |
| Adc Therapeutics America, INC. | $22.78 | 2024 | |
| Puma Biotechnology, INC. | $21.45 | 2025 | |
| Sobi, INC | $21.20 | 2022 | |
| Horizon Therapeutics Plc | $20.69 | 2023 | Tepezza |
| Agios Pharmaceuticals, INC. | $19.59 | 2022 | |
| Exact Sciences Corporation | $19.47 | 2025 | The Cologuard Plus Collection Kit |
| Array Biopharma INC | $19.45 | 2021 | |
| Servier Pharmaceuticals LLC | $19.35 | 2024 | |
| Eusa Pharma (US) LLC | $17.54 | 2020 | |
| Deciphera Pharmaceuticals INC. | $16.84 | 2021 | |
| Myovant Sciences INC. | $15.67 | 2022 | |
| Myriad Genetic Laboratories, INC. | $15.01 | 2024 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.